Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
PGNX's Cash-to-Debt is ranked higher than
98% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. PGNX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
PGNX' s Cash-to-Debt Range Over the Past 10 Years
Min: 65  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.71
PGNX's Equity-to-Asset is ranked higher than
60% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. PGNX: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
PGNX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.88 Max: 0.98
Current: 0.71
0.31
0.98
Interest Coverage No Debt
PGNX's Interest Coverage is ranked higher than
98% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PGNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PGNX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 6.52
Beneish M-Score: 16.49
WACC vs ROIC
29.46%
85.21%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % 14.98
PGNX's Operating Margin % is ranked higher than
81% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. PGNX: 14.98 )
Ranked among companies with meaningful Operating Margin % only.
PGNX' s Operating Margin % Range Over the Past 10 Years
Min: -878.82  Med: -71.63 Max: 14.98
Current: 14.98
-878.82
14.98
Net Margin % 15.55
PGNX's Net Margin % is ranked higher than
84% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. PGNX: 15.55 )
Ranked among companies with meaningful Net Margin % only.
PGNX' s Net Margin % Range Over the Past 10 Years
Min: -876.82  Med: -64.28 Max: 15.55
Current: 15.55
-876.82
15.55
ROE % 12.07
PGNX's ROE % is ranked higher than
85% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. PGNX: 12.07 )
Ranked among companies with meaningful ROE % only.
PGNX' s ROE % Range Over the Past 10 Years
Min: -87.75  Med: -33.65 Max: 16.86
Current: 12.07
-87.75
16.86
ROA % 8.18
PGNX's ROA % is ranked higher than
87% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. PGNX: 8.18 )
Ranked among companies with meaningful ROA % only.
PGNX' s ROA % Range Over the Past 10 Years
Min: -79.08  Med: -25.15 Max: 14.53
Current: 8.18
-79.08
14.53
ROC (Joel Greenblatt) % 355.28
PGNX's ROC (Joel Greenblatt) % is ranked higher than
96% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. PGNX: 355.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PGNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1585.16  Med: -413.77 Max: 355.28
Current: 355.28
-1585.16
355.28
3-Year Revenue Growth Rate -32.50
PGNX's 3-Year Revenue Growth Rate is ranked lower than
79% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. PGNX: -32.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PGNX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -55.5  Med: -16.7 Max: 72.1
Current: -32.5
-55.5
72.1
3-Year EBITDA Growth Rate -17.30
PGNX's 3-Year EBITDA Growth Rate is ranked lower than
68% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. PGNX: -17.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PGNX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -46.4  Med: -8.1 Max: 51.1
Current: -17.3
-46.4
51.1
3-Year EPS without NRI Growth Rate -18.10
PGNX's 3-Year EPS without NRI Growth Rate is ranked lower than
66% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. PGNX: -18.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PGNX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -73.5  Med: -6.15 Max: 221.4
Current: -18.1
-73.5
221.4
GuruFocus has detected 4 Warning Signs with Progenics Pharmaceuticals Inc $PGNX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PGNX's 10-Y Financials

Financials (Next Earnings Date: 2017-03-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PGNX Guru Trades in Q1 2016

Ken Fisher 140,191 sh (unchged)
Murray Stahl 67,200 sh (unchged)
Paul Tudor Jones 2,364,488 sh (-0.26%)
Chuck Royce 2,138,350 sh (-6.31%)
» More
Q2 2016

PGNX Guru Trades in Q2 2016

Mario Gabelli 25,000 sh (New)
Ken Fisher 140,361 sh (+0.12%)
Murray Stahl 67,200 sh (unchged)
Paul Tudor Jones 2,342,388 sh (-0.93%)
Chuck Royce 1,913,350 sh (-10.52%)
» More
Q3 2016

PGNX Guru Trades in Q3 2016

Joel Greenblatt 48,873 sh (New)
Murray Stahl 67,200 sh (unchged)
Chuck Royce 1,728,350 sh (-9.67%)
Ken Fisher 107,663 sh (-23.30%)
Mario Gabelli 17,000 sh (-32.00%)
Paul Tudor Jones 287,813 sh (-87.71%)
» More
Q4 2016

PGNX Guru Trades in Q4 2016

Joel Greenblatt 529,614 sh (+983.65%)
Murray Stahl 67,200 sh (unchged)
Mario Gabelli Sold Out
Chuck Royce 1,459,174 sh (-15.57%)
Ken Fisher 79,028 sh (-26.60%)
Paul Tudor Jones 4,200 sh (-98.54%)
» More
» Details

Insider Trades

Latest Guru Trades with PGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ANIK, OTCPK:SXMDF, NAS:CLLS, OTCPK:GNFTF, NAS:ANIP, NAS:VSAR, OTCPK:PHMMF, NAS:AMRI, NAS:AMAG, NAS:ZIOP, NAS:ARDX, NAS:VNDA, NAS:FOLD, NAS:INSY, OTCPK:IPHYF, NAS:INSM, NAS:AMRN, NAS:ESPR, OTCPK:BPMUF, NAS:KERX » details
Traded in other countries:PGP.Germany,
Progenics Pharmaceuticals Inc is engaged in the development of medicines for oncology. The Company develops products for the treatment of prostate cancer, opioid-induced constipation, or OIC, as well as OIC for non-cancer pain.

Progenics Pharmaceuticals Inc was incorporated in Delaware on December 1, 1986. The Company is engaged in the development of medicines for oncology. Its clinical development centers on late-stage oncology assets. Its product candidates are RELISTOR in injection form for the treatment of opioid induced constipation, or OIC. RELISTOR has received a complete response letter on the pending sNDA for the treatment of OIC in patients with non-cancer pain. The Company, along with Salix Pharmaceuticals, develops and commercializes subcutaneous Relistor internationally other than in Japan. The Company's clinical-stage products in oncology are PSMA ADC, 1404, and Azedra. The PSMA ADC is for the treatment of prostate cancer and is in the Phase 2 testing in chemotherapy-experienced patients completed. The Phase 2 testing is completed on 1404, an imaging agent for prostate cancer. Azedra is in Phase 2b registrational trial under Special Protocol Assessment for the treatment of pheochromocytoma and paraganglioma. The Company and its product candidates is subject to regulations by the U.S. FDA as well as authorities in other countries. The Company faces competition from other companies, universities and research institutions in the U.S. and abroad.

Ratios

vs
industry
vs
history
PE Ratio 64.75
PGNX's PE Ratio is ranked lower than
78% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 26.13 vs. PGNX: 64.75 )
Ranked among companies with meaningful PE Ratio only.
PGNX' s PE Ratio Range Over the Past 10 Years
Min: 12.75  Med: 75.29 Max: 925
Current: 64.75
12.75
925
PE Ratio without NRI 64.75
PGNX's PE Ratio without NRI is ranked lower than
77% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 26.61 vs. PGNX: 64.75 )
Ranked among companies with meaningful PE Ratio without NRI only.
PGNX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.75  Med: 75.29 Max: 925
Current: 64.75
12.75
925
Price-to-Owner-Earnings 59.88
PGNX's Price-to-Owner-Earnings is ranked lower than
75% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 25.00 vs. PGNX: 59.88 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PGNX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 22.12  Med: 51.79 Max: 144.53
Current: 59.88
22.12
144.53
PB Ratio 6.54
PGNX's PB Ratio is ranked lower than
71% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. PGNX: 6.54 )
Ranked among companies with meaningful PB Ratio only.
PGNX' s PB Ratio Range Over the Past 10 Years
Min: 1.08  Med: 3.54 Max: 8.82
Current: 6.54
1.08
8.82
PS Ratio 10.41
PGNX's PS Ratio is ranked lower than
51% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. PGNX: 10.41 )
Ranked among companies with meaningful PS Ratio only.
PGNX' s PS Ratio Range Over the Past 10 Years
Min: 1.88  Med: 8.77 Max: 177.27
Current: 10.41
1.88
177.27
Price-to-Free-Cash-Flow 55.11
PGNX's Price-to-Free-Cash-Flow is ranked lower than
75% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 23.86 vs. PGNX: 55.11 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PGNX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.01  Med: 32.59 Max: 278.57
Current: 55.11
11.01
278.57
Price-to-Operating-Cash-Flow 43.90
PGNX's Price-to-Operating-Cash-Flow is ranked lower than
72% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 22.05 vs. PGNX: 43.90 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PGNX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.86  Med: 30.55 Max: 205.26
Current: 43.9
10.86
205.26
EV-to-EBIT 59.88
PGNX's EV-to-EBIT is ranked lower than
83% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 18.89 vs. PGNX: 59.88 )
Ranked among companies with meaningful EV-to-EBIT only.
PGNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -50.8  Med: -3.25 Max: 301.4
Current: 59.88
-50.8
301.4
EV-to-EBITDA 50.17
PGNX's EV-to-EBITDA is ranked lower than
83% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 16.23 vs. PGNX: 50.17 )
Ranked among companies with meaningful EV-to-EBITDA only.
PGNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -132.8  Med: -3.4 Max: 233.2
Current: 50.17
-132.8
233.2
Current Ratio 7.71
PGNX's Current Ratio is ranked higher than
77% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. PGNX: 7.71 )
Ranked among companies with meaningful Current Ratio only.
PGNX' s Current Ratio Range Over the Past 10 Years
Min: 2.67  Med: 11.42 Max: 32.92
Current: 7.71
2.67
32.92
Quick Ratio 7.71
PGNX's Quick Ratio is ranked higher than
78% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. PGNX: 7.71 )
Ranked among companies with meaningful Quick Ratio only.
PGNX' s Quick Ratio Range Over the Past 10 Years
Min: 2.67  Med: 11.42 Max: 32.92
Current: 7.71
2.67
32.92
Days Sales Outstanding 20.59
PGNX's Days Sales Outstanding is ranked higher than
81% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. PGNX: 20.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
PGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.36  Med: 32.86 Max: 180.24
Current: 20.59
0.36
180.24

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.50
PGNX's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. PGNX: -14.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PGNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -73.6  Med: -11.6 Max: -2.1
Current: -14.5
-73.6
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 13.81
PGNX's Price-to-Net-Cash is ranked lower than
67% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. PGNX: 13.81 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PGNX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.59  Med: 6.44 Max: 22.41
Current: 13.81
1.59
22.41
Price-to-Net-Current-Asset-Value 12.05
PGNX's Price-to-Net-Current-Asset-Value is ranked lower than
71% of the 387 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. PGNX: 12.05 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PGNX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.48  Med: 5.85 Max: 18.68
Current: 12.05
1.48
18.68
Price-to-Tangible-Book 10.80
PGNX's Price-to-Tangible-Book is ranked lower than
78% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. PGNX: 10.80 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PGNX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.22  Med: 5.13 Max: 13.49
Current: 10.8
1.22
13.49
Price-to-Median-PS-Value 1.19
PGNX's Price-to-Median-PS-Value is ranked lower than
62% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. PGNX: 1.19 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PGNX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 1.41 Max: 15.05
Current: 1.19
0.26
15.05
Price-to-Graham-Number 5.56
PGNX's Price-to-Graham-Number is ranked lower than
78% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 2.51 vs. PGNX: 5.56 )
Ranked among companies with meaningful Price-to-Graham-Number only.
PGNX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.02  Med: 4.19 Max: 15.87
Current: 5.56
2.02
15.87
Earnings Yield (Greenblatt) % 1.70
PGNX's Earnings Yield (Greenblatt) % is ranked higher than
75% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. PGNX: 1.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PGNX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.3  Med: 2 Max: 10.2
Current: 1.7
0.3
10.2

More Statistics

Revenue (TTM) (Mil) $69.87
EPS (TTM) $ 0.16
Beta3.61
Short Percentage of Float18.15%
52-Week Range $3.80 - 10.84
Shares Outstanding (Mil)70.05

Analyst Estimate

Dec16 Dec18
Revenue (Mil $) 73 123
EPS ($) 0.14 0.55
EPS without NRI ($) 0.14 0.55
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PGNX

Headlines

Articles On GuruFocus.com
Tiger Management’s Julian Robertson Buys Alibaba, eBay, MasTec, Sells Tableau Software, Monsanto, Nov 14 2014 
Ex-Boxer Paul Tudor Jones Delivering Knockout Punches on Wall Street Nov 07 2014 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 27 2013 
Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX Oct 01 2012 
5 Stocks That Dropped the Most Since Gurus Bought Them Sep 13 2012 
Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Dec 01 2010 
Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Nov 02 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Oct 04 2010 

More From Other Websites
Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2016 Financial Results Call for March 9 Feb 23 2017
Biotech Premarket Movers: Progenics, Alexion, BioCryst Feb 16 2017
Progenics Pharmaceuticals and Shutterfly to Join S&P SmallCap 600 Feb 15 2017
Progenics Pharmaceuticals Announces Initiation of a Phase 1 Clinical Trial of its PSMA-Targeted... Feb 14 2017
Progenics Pharmaceuticals, Inc. to Participate in February Investor Conferences Feb 08 2017
Progenics Pharm upgraded by Needham Feb 06 2017
Progenics Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PGNX) : January 30, 2017 Jan 30 2017
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change... Jan 30 2017
Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PGNX-US :... Jan 27 2017
ETFs with exposure to Progenics Pharmaceuticals, Inc. : January 20, 2017 Jan 20 2017
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jan 09 2017
My Top 2017 Pick: Progenics Pharmaceuticals Jan 03 2017
Progenics shares rally as prostate cancer imaging study to continue Dec 22 2016
Progenics Pharmaceuticals Announces Independent Committee's Positive Recommendation for Continuation... Dec 22 2016
Progenics Pharmaceuticals Announces Independent Committee’s Positive Recommendation for... Dec 22 2016
ETFs with exposure to Progenics Pharmaceuticals, Inc. : December 12, 2016 Dec 12 2016
Is Progenics Pharmaceuticals, Inc. (PGNX) a Good Stock to Buy? Dec 09 2016
Progenics Pharmaceuticals Announces First Patient Dosed in Phase 2/3 Clinical Trial of PSMA-Targeted... Dec 07 2016
Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor Nov 30 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)